MAGEC2 and melanoma: Notably, 27% of patients with stage III or stage IV melanoma who were immunized using dendritic cells loaded with mRNA encoding the melanoma-associated antigens MAGE-A3, MAGE-C2, tyrosinase, gp100, and TriMix showed tumor regressions (179).